Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData Read more
J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend: GlobalData Read more
AbbVie’s $10.1 bn Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC investment surge: GlobalData Read more
Eisai, Bristol Myers Squibb enter collaboration for Eisai’s MORAb-202 antibody-drug conjugate Read more